脓毒症并发毛细血管渗漏综合征的研究进展

doi:10.16352/j.issn.1001-6325.2022.07.1144

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (7): 1144-1147.doi: 10.16352/j.issn.1001-6325.2022.07.1144

脓毒症并发毛细血管渗漏综合征的研究进展

林柏柏¹, 钱风华², 钱义明², 赵雷², 孙旗¹, 褚梦瑶¹, 沈梦雯^2*

1.上海中医药大学,上海 200080;
2.上海中医药大学附属岳阳中西医结合医院急诊医学科,上海 200437

收稿日期:2020-10-26 修回日期:2021-04-06 出版日期:2022-07-05 发布日期:2022-06-29
通讯作者: * hupo_58@163.com
基金资助:
上海中医药大学附属岳阳中西医结合医院基金青年项目(2019YYQ07)

Research progress of sepsis complicated with capillary leakage syndrome

LIN Bai-bai¹, QIAN Feng-hua², QIAN Yi-ming², ZHAO Lei², SUN Qi¹, CHU Meng-yao¹, SHEN Meng-wen^2*

1. Shanghai University of Traditional Chinese Medicine, Shanghai 200080;
2. Department of Emergency Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China

Received:2020-10-26 Revised:2021-04-06 Online:2022-07-05 Published:2022-06-29
Contact: * hupo_58@163.com

摘要/Abstract

摘要： 脓毒症(sepsis)具有高发病率,是一种常见的、可致命的疾病。脓毒症是指因感染引起的宿主反应失调导致危及生命的器官功能障碍,部分患者还会出现低蛋白血症、低血压、少尿、水肿等现象,即毛细血管渗漏综合征(CLS)。脓毒症合并CLS是较复杂的疾病,对于此类患者,需要给予积极的治疗,然治疗讲究针对性、有效性,因此,深入理解此疾病的发病机制,并且结合临床治疗经验对临床工作有重要的意义。

关键词: 脓毒症, 毛细血管渗漏综合征, 发病机制, 临床治疗

Abstract: Sepsis is a common and fatal disease with high mortality. Sepsis is a life-threatening organ dysfunction caused by abnormal host response to infection. Some patients also complicate with hypo-albuminemia, hypotension, oliguria, edema and other phenomena, namely capillary leakage syndrome (CLS). Sepsis with CLS is a complex disease urgently needs active treatment, but a successful treatment must be based on in-depth understanding of the pathogenesis and combined with clinical treatment experience.

Key words: sepsis, capillary leakage syndrome, pathogenesis, clinical treatment

中图分类号:

R364

林柏柏, 钱风华, 钱义明, 赵雷, 孙旗, 褚梦瑶, 沈梦雯. 脓毒症并发毛细血管渗漏综合征的研究进展[J]. 基础医学与临床, 2022, 42(7): 1144-1147.

LIN Bai-bai, QIAN Feng-hua, QIAN Yi-ming, ZHAO Lei, SUN Qi, CHU Meng-yao, SHEN Meng-wen. Research progress of sepsis complicated with capillary leakage syndrome[J]. Basic & Clinical Medicine, 2022, 42(7): 1144-1147.

参考文献 28

[1]	Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315: 801-810.
[2]	Ma S, Evans RG, Iguchi N, et al. Sepsis-induced acute kidney injury: a disease of the microcirculation[J]. Microcirculation, 2019, 26: e12483. doi: 10.1111/micc.12483.
[3]	Hajare KR, Patil P, Bansode J. Idiopathic systemic capillary leak syndrome[J]. Indian J Crit Care Med, 2018, 22: 369-371.
[4]	Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management[J]. Kidney Int, 2017, 92: 37-46.
[5]	Mertz P, Lebrun-Vignes B, Salem JE, et al. Characteriz-ing drug-induced capillary leak syndromes using the World Health Organization VigiBase[J]. J Allergy Clin Immunol, 2019, 143: 433-436.
[6]	Xie Z, Ghosh CC, Patel R, et al. Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)[J]. Blood, 2012, 119: 4321-4332.
[7]	Xu D, Liu T, Lin L, et al. Exposure to endosulfan increases endothelial permeability by transcellular and paracellular pathways in relation to cardiovascular diseases[J]. Environ Pollut, 2017, 223: 111-119.
[8]	Takeuchi O, Akira S. Pattern recognition receptors and inflammation[J]. Cell, 2010, 140: 805-820.
[9]	D'Elia RV, Harrison K, Oyston PC, et al. Targeting the “cytokine storm” for therapeutic benefit[J]. Clin Vaccine Immunol, 2013, 20: 319-327.
[10]	Raymond SL, Holden DC, Mira JC, et al. Microbial recognition and danger signals in sepsis and trauma[J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863: 2564-2573.
[11]	Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nat Immunol, 2010, 11: 373-384.
[12]	Akwii RG, Sajib MS, Zahra FT, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology[J]. Cells, 2019, 8: 471.doi:10.3390/cells8050471.
[13]	Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease)[J]. J Allergy Clin Immunol, 2017, 140: 663-670.
[14]	Geranmayeh MH, Rahbarghazi R, Farhoudi M. Targeting pericytes for neurovascular regeneration[J]. Cell Commun Signal, 2019, 17: 26. doi: 10.1186/s12964-019-0340-8.
[15]	Claesson-Welsh L. Vascular permeability--the essentials[J]. Ups J Med Sci, 2015, 120:135-143.
[16]	王永玲, 李冬霞, 高建芝, 等.VEGF在肥胖患者乳腺癌组织中的表达及临床意义[J].基础医学与临床, 2012, 32: 544-547.
[17]	Li X, Padhan N, Sjöström EO, et al. VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread[J]. Nat Commun, 2016, 7: 11017. doi:10.1038/ncomms11017.
[18]	Heinolainen K, Karaman S, D'Amico G, et al. VEGFR3 modulates vascular permeability by controlling VEGF/VEGFR2 signaling[J]. Circ Res, 2017, 120: 1414-1425.
[19]	Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific cross-MAb optimized for neovascular eye diseases[J]. EMBO Mol Med, 2016, 8: 1265-1288.
[20]	许小泽, 刘雪燕, 郑标林, 等. 脓毒症毛细血管渗漏综合征的机制及临床治疗探究[J].当代医学, 2020, 26: 189-191.
[21]	黄增相, 何超, 陶骅, 等. 肠源性脓毒症并发肺毛细血管渗漏综合征一例救治[J].中国呼吸与危重监护杂志, 2015, 14: 98-100.
[22]	王晓锋, 瞿金龙. 乌司他丁治疗急性呼吸窘迫综合征的临床研究[J].交通医学, 2019, 33: 574-576.
[23]	陈豆豆, 常青, 章向成, 等. 连续性肾脏替代治疗对严重脓毒症患者肾功能及微循环的影响[J]. 广西医科大学学报, 2017, 34: 851-854.
[24]	Das M, Karnam A, Stephen-Victor E, et al. Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy[J]. Cell Death Dis,2020,11: 50. doi: 10.1038/s41419-020-2249-y.
[25]	贺周香. 免疫球蛋白对脓毒症患者血管内皮功能的影响[J].中外医学研究, 2019, 17: 52-53.
[26]	Liu S, Yao C, Zhang J, et al. Efficacy of Xuebijing Injection for sepsis (EXIT-SEP): protocol for a randomised controlled trial[J]. BMJ Open, 2019, 9: e028664. doi: 10.1136/bmjopen-2018-028664.
[27]	张利鹏, 张立彦, 王雪芳, 等. 血必净联合西医治疗老年毛细血管渗漏综合征的疗效及对血压、血清炎症因子的影响[J].实用老年医学, 2017, 31: 462-465.
[28]	Chen G, Gao Y, Jiang Y, et al. Efficacy and safety of xuebijing injection combined with ulinastatin as adjunctive therapy on sepsis: a systematic review and meta-analysis[J]. Front Pharmacol, 2018, 9: 743. doi: 10.3389/fphar.2018.00743.

脓毒症并发毛细血管渗漏综合征的研究进展

Research progress of sepsis complicated with capillary leakage syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[2]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[3]	彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.
[4]	张雅慧, 白琼. 低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 114-118.
[5]	蒋琪, 杨柳, 和娇娇, 李维辛. 脂毒性在肌少症发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(12): 1886-1890.
[6]	孙晓丽, 张进进, 宋凤英, 黄永莉, 陈立力, 邢颜超. Tim-3/galectin-9调控脂多糖诱导的人淋巴细胞中Th1/Th2细胞平衡[J]. 基础医学与临床, 2023, 43(10): 1542-1548.
[7]	周嘉航, 陈鋆瑶, 曹红翠. 间充质干细胞移植治疗肝脏疾病的研究进展[J]. 基础医学与临床, 2023, 43(1): 12-20.
[8]	孙慧, 陈思宇. 微生物相关肿瘤的发病机制及其治疗的研究进展[J]. 基础医学与临床, 2023, 43(1): 178-182.
[9]	王英臣, 孙立群. 二肽基肽酶Ⅲ在治疗脓毒症中的应用进展[J]. 基础医学与临床, 2023, 43(1): 196-199.
[10]	薛晋芳, 宋海飞, 陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[11]	匡重伸, 丛竹凯, 吴长毅, 杨宁, 宗亚楠, 郭向阳. 内脂素在脓毒症相关性脏器损伤中的作用及机制研究进展[J]. 基础医学与临床, 2022, 42(8): 1279-1283.
[12]	赵肖灵, 何润之, 孙玉姣, 张小冲, 杨林芳, 王瑞, 程芳. 活动期白癜风患者血清γ干扰素含量升高[J]. 基础医学与临床, 2022, 42(7): 1067-1070.
[13]	温燕, 林金灿, 黄颖泓, 肖文彪, 张民伟, 林建东. 脓毒症早期BMP-2和BMP-4的变化[J]. 基础医学与临床, 2022, 42(4): 628-632.
[14]	石丹丹, 蒋素芳, 王茜, 赵鹏博, 刘雅. IL-6反式信号传导通路抑制剂sgp130Fc抑制脓毒症小鼠炎性反应及调节免疫细胞[J]. 基础医学与临床, 2022, 42(12): 1895-1899.
[15]	吴长宝, 郝延磊. STAT3与帕金森病发病机制的研究进展[J]. 基础医学与临床, 2022, 42(12): 1935-1938.